Limba
|
Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD.
| Price | 9.330,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD. |